Cancer is second leading cause of deaths globally which took close to 9.6 Mn lives in 2018. Almost 46% of people died due to cancer were 70 years or older, whereas over 70% of the people died in low-middle income countries. The developed regions such as North America and Western Europe have very good resources to fight with this disease. Whereas many other countries don’t have enough resources to fully fight the disease due to its huge treatment cost and other factors. The two factors mentioned above such as high fatality rate in older people as well as in low-middle income countries show a very worrying trend. The financial strain of treatment both on government budgets as well as on people is a very big factor behind emergence and more R&D in Biosimilars. Globally the market is expected to increase by 10-12% y-o-y till 2025.
Biosimilars in Oncology
Rituximab: EU have already approved first Biosimilar of Rituximab. Truxima by Celltrion Healthcare is licensed for the treatment of chronic lymphocytic lymphoma (CLL), non-Hodgkin’s follicular lymphoma, and diffuse large B-cell lymphoma – for which MabThera is widely used. In US it was launched in Nov 2019 at 10% less price than reference medicine.
Trastuzumab: Ontruzant, produced by Samsung Bioepis, became the first biosimilar to Traztuzumab to get approval in EU. It can be used as a monotherapy or in combination with chemotherapy or hormone therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Next line of Biosimilars approved in EU includes Herzuma (Celltrion Healthcare Hungary Kft.), Kanjinti (Amgen Europe), Trazimera (Pfizer Europe) and Ogivri (Mylan S.A.S.).
Similarly biosimilars for other reference products such as Bevacizumab, Filgrastim and pegfilgrastrim, Epoetins, etc. are also active in EU & US, as well as the companies are investing in more R&D to bring more biosimilars in the markets.
Biocon: Biocon, in collaboration with Mylan, got US FDA acceptance for one of this recent Biosimilars to Avastin. The drug, which is used to treat patients of lung, cervical, and colorectal cancer, is already available in many developing markets.
Pfizer: In 2019, Pfizer for US FDA approval for its Biosimilar, ZIRABEV™ (bevacizumab-bvzr), to Avastin. The biosimilar is useful for treatment in 5 types of cancers. In EU it received approval for its Biosimilar, RUXIENCE™, a monoclonal antibody, to Rituximab.
Competitive Profiles and Future Pipeline Analysis for companies such as Biocon, Mylan, Sandoz, Pfizer, Samsung Bioepis, Teva, Celltrion, Coherus Biosciences, Amgen Inc., Hospira Inc., Ratiopharm GmbH, Apotex Europe Bv, etc.
By Product Type
By Cancer Type
By Distribution Channel
To get a copy of Table of Contents (ToC), Report Blue Print or Sample Copy please Click HERE
To get a copy of List of Deliverables please share your requirements HERE
We offer customized reports as per our customers requirements. This covers a 360 degree deliverable scope study such as:
This section covers very brief quick reports as a scale down version of original Market Research report. You may be any of the following:
Please don’t worry and write to us HERE
For any other discussion such as related to various reports, future business requirements, feasibility discussion, etc. Or for talk to our sales team executive please feel free to reach out to us HERE